AbbVie Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: AbbVie Inc. vs Axsome Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AbbVie Inc. and Axsome Therapeutics, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. AbbVie, a giant in the sector, has seen its SG&A expenses grow by approximately 66% from 2014 to 2023, peaking in 2022. This reflects its aggressive expansion and marketing strategies. In contrast, Axsome Therapeutics, a smaller player, has experienced a staggering increase of over 23,000% in the same period, highlighting its rapid growth and investment in market penetration. These trends underscore the differing scales and strategies of established versus emerging pharmaceutical companies. As the industry continues to innovate, monitoring these financial metrics provides valuable insights into corporate priorities and market dynamics.